TROG Cancer Research
Members Login   CQMS Login

TROG Publications

TROG has had over 200 publications in national and international journals spanning the last 25 years:

TROG Annual Citation Report - 2017

TROG Annual Citation Report - 2018

Bladder, Kidney & Prostate - Brain & Central Nervous System - Breast - Gastrointestinal - GynaecologicalHead & Neck - Lung - Lymphoma - Skin - Symptom Management - TROG Projects - Other 

Most Recent Publications (Publications since Jan 2019)

12.03 EAT

Britton B, Baker A, Wolfenden L, Wratten C, Bauer J, Beck A, McCarter K, Harrowfield J, Isenring E, Tang C, Oldmeadow C, Carter G. Eating As Treatment (EAT): a stepped-wedge, randomised controlled trial of a health behaviour change intervention provided by dietitians to improve nutrition in patients with head and neck cancer undergoing radiotherapy (TROG 12.03). Int J Radiat Oncol Biol Phys. 2019 Feb; 103(2):353-62. DOI: 10.1016/j.ijrobp.2018.09.027

 
09.02  CHISEL 

Ball D, Mai T, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vaneski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Le H. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019 Feb; Online First. DOI: 10.1016/S1470-2045(18)30896-9

 
03.04  RADAR 

Denham J, Joseph D, Lamb D, Spry N, Duchesne G, Matthews J, Atkinson C, Tai K, Christie D, Kenny L, Turner S, Gogna K, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2019 Feb; 20(2):267-81. DOI: 10.1016/S1470-2045(14)70328-6

 
03.03 -

Wirth A, Prince H, Roos D, Gibson J, O'Brien P, Zannino D, Khodr B, Stone J, Davis S, Hertzberg M. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03). Int J Radiat Oncol Biol Phys. 2019 Apr; 103(5):1158-66. DOI: 10.1016/j.ijrobp.2018.12.006

 

Bladder, Kidney & Prostate

15.01 SPARK

Legge K, Greer P, Keall P, Booth J, Arumugam S, Moodie T, Nguyen D, Martin J, O'Connor D, Lehmann J. Technical Note: TROG 15.01 SPARK Trial Multi-Institutional Imaging Dose Measurement. J Appl Clin Med Phys. 2017 Jul; 18(5):358-63
DOI: 10.1002/acm2.12151

15.01 SPARK

Ngyuen D, O'Brien R, Kim J, Huang C, Booth J, Wilton L, Greer P, Legge K, Poulsen P, Martin J, Keall P. The First Clinical Implementation of a Real-Time Six Degree Of Freedom Tracking System For Intrafaction Prostate Motion During Radiation Therapy. Radiother and Oncol. 2017 April; 123(1):37-42
DOI: 10.1016/j.radonc.2017.02.013

15.01 SPARK

Keall P, Nguyen T, O'Brien R, Booth J, Greer P, Poulsen P, Gebski V, Kneebone A, Martin J. Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: the TROG 15.01 SPARK trial. BMC Cancer. 2017 Mar; 17(1):180
DOI: 10.1186/s12885-017-3164-1

 10.01 

 BOLART 

Foroudi F, Pham D, Rolfo A, Bressel M, Tang C, Tan A, Turner S, Hruby G, Williams S, Hayne D, Lehman M, Skala M, Jose C, Gogna K, Kron T.  The outcome of a multi-centre feasibility study of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer TROG 10.01 BOLART.  Radiother Oncol. 2014 May; 111(2):316-20.

10.01

BOLART

Foroudi F, Pham D, Bressel M, Tongs D, Rolfo A, styles C, Gill S, Kron T.  The utility of e-Learning to support training for a multicentre bladder online adaptive radiotherapy trial (TROG 10.01-BOLART). Radiother Oncol. 2013 Oct; 109(1):165-69. 

10.01

BOLART

Pham D, Roxby P, Kron T, Rolfo A, Foroudi F. Introduction of Online Adaptive Radiotherapy for Bladder Cancer through a Multicentre Clinical Trial (TROG 10.01): Lessons Learned. Jour Med Phys. 2013 Apr; 38(2):59-66. 

10.01

BOLART

Kron T, Pham D, Roxby P, Rolfo A, Foroudi F. Credentialing of radiotherapy centres for a clinical trial of adaptive radiotherapy for bladder cancer (TROG 10.01). Radiother Oncol, 2012 Jun; 103(3):293-98.

08.03 RAVES

Sundaresan P, Ager B, Turner S, Costa D, Kneebone A, Pearse M, et al. A randomised controlled trial evaluating the utility of a patient Decision Aid to improve clinical trial (RAVES 08.03) related decision-making. Radiother Oncol. 2017 Oct; 125(1): 124-29.
DOI: 10.1016/j.radonc.2017.08.013

08.03

RAVES

Trada Y, Kneebone A, Paneghel A, Pearse M, Sidhom M, Tang C, Wiltshire K, Haworth K, Fraser-Browne C, Martin J. Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy. Int J Radiat Oncol Biol Phys. 2015 Dec; 93(5):1045-51.  

08.03

RAVES

Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, Woo HH.  Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early Lessons from the 08.03 RAVES Trial. J Clin Oncol. 2014 Jun; 26(6):348-52.

08.03

RAVES

Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim T, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Williams SG, Wiltshire K, Woo HH, Kneebone A. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the RAVES trial (Radiotherapy Adjuvant Versus Early Salvage). BJUI. 2014 Mar; 113(S2):7-12.

08.03

RAVES

Sundaresan P, Turner S, Kneebone A, Pearse M, Butow P. Evaluating the utility of a patient decision aid for potential participants of a prostate cancer trial (RAVES-TROG 08.03). Radiother Oncol. 2011 Dec; 101(3):521-524.

08.01 PROFIT

Catton C, Lukka H, Gu C, Martin J, Supiot S, Chung P, Bauman G, Bahary J, Ahmed S, Cheung P, Tai KH, Wu J, Parliament M, Tsakiridis T, Corbett T, Tang C, Days I, Warde P, Craig T, Julian J, Levine M. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology. 2017 Jun; 35(17):1884-907
DOI: 10.1200/JCO.2016.71.7397

08.01

PROFIT

Healy B, Frantzis J, Murry R, Martin J, Plank A, Middleton M, Catton C, Kron T. Results from a multicentre prostate IMRT dosimetry intercomparison for an OCOG-TROG clinical trial. Med Phys. 2013 Jul; 40(7):071706. 

08.01

PROFIT

Martin J, Frantzis J, Chung P, Langah I, Crain M, Cornes D, Plank A, Finch T, Jones M, Khoo E, Catton C. Prostate Radiotherapy Clinical Trial Quality Assurance: How Real Should Real Time Review Be? (A TROG-OCOG Intergroup Project). Radiother Oncol. 2013 Jun; 107(3):333-38.

08.01

PROFIT

Healy B, Frantzis J, Murry R, Martin J, Middleton M, Catton C, Kron T. Development of a dosimetry inter-comparison for IMRT as part of site credentialing for a TROG multi-centre clinical trial for prostate cancer. Australas Phys Eng Sci Med. 2011 Jun; 34(2):195-202. 

08.01

PROFIT

Middleton M, Frantzis J, Healy B, Jones M, Murry R, Kron T, Plank A, Catton C, Martin J. Successful Implementation of Image Guided radiation therapy Quality Assurance in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. Int J Rad Onc Biol Phys. 2011 Dec; 81(5):1576-81. 

03.06 TOAD

Duchesne G, Woo H, King M, Bowe S, Stockler M, Ames A, et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol.  2017 Sep; 18(9):1192-1201.
DOI: 10.1016/S1470-2045(17)30426-6

03.06 TOAD

Duchesne G, Woo H, Bassett J, Bowe S, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith R, Spry N, Stockler M, Syme R, Tai K, Turner S. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): A randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016 Jun; 17(6):727-37

03.06

TOAD

Duchesne G, Haworth A, Bone E, Carter H, Ebert M, Gagliardi F, Gibbs A, Hornby C, Martin A, Sidhom M, Wood M, Jackson M. Testing the Assessment of New Radiation Oncology Technologyand Treatments framework using the evaluation of post-prostatectomy radiotherapy techniques. J Med Imag Radiat Oncol. 2016 Feb; 60(1):129-37.

03.06

TOAD

Duchesne GM, Woo HH, Howell D, Kaimakamis M, Kemp E. Tribulations of a prostate cancer trial – lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial. J Med Imag Radiat Oncol. 2010 Oct; 54(5):508-11. 

03.06

TOAD

Duchesne, GM, Syme R, Howell D. How early is early: Androgen deprivation for prostate-specific antigen relapse in prostate cancer. J Clin Oncol. 2006 June; 24(18):2964-64. 

03.04 RADAR

Bitska V, Sharpley CF,  Bradford R, Steigler A, Denham JW.  Measuring Personal and Functional Changes in Prostate Cancer Survivors: Development and validation of the FADE: Data from the TROG 03.04 RADAR trial.  Psycho-Oncology. 2017 Apr; 26(4):553-55.
DOI: 10.1002/pon.4182

03.04 RADAR Marcello M, Ebert M, Haworth A, Steigler A, Kennedy A, Joseph D, Denham J. Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. Radioth Oncol. 2018 Feb; 126(2):249-56.
DOI: 10.1016/j.radonc.2017.10.021
03.04 RADAR Marcello M, Ebert M, Haworth A, Steigler A, Kennedy A, Bulsara M, Kearvell R, Joseph D, Denham J. Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. J Med Imag Radiat Oncol. Article in press.
DOI: 10.1111/1754-9485.12695
03.04 RADAR

Yahya N, Ebert MA, House MJ, Kennedy A, Matthews J, Joseph DJ, Denham JW. Modeling Urinary Dysfunction After External Beam Radiation Therapy of the Prostate Using Bladder Dose-Surface Maps: Evidence of Spatially Variable Response of the Bladder Surface. Int J Radiat Oncol Biol Phys. 2017 Feb; 97(2):420-6.
DOI: 10.1016/j.ijrobp.2016.10.024

 03.04   RADAR 

Sharpley, C.F., Bitsika, V., Christie, D.R.H., Bradford, R., Steigler, A., & Denham, J.W. Total Depression and Subtypes in Prostate Cancer Survivors 10 years after treatment. Eur J Cancer Care. 2017 Nov; 26(6):e12630.
DOI: 10.1111/ecc.12630

 03.04 

 RADAR 

Bitsika V, Sharpley CF, Bradford R, Steigler A, Denham JW.  Measuring Personal and Functional Changes in Prostate Cancer Survivors: Development and validation of the FADE: Data from the TROG 03.04 RADAR trial.  Psycho-Oncology. 2017 Apr; 26(4):553-55.
DOI: 10.1002/pon.4182

03.04 RADAR

Cicchetti A, Rancati T, Ebert M, Fiorino C, Palorini F, Kennedy A, Joseph DJ, Denham JW, Vavassori V, Fellin G, Avuzzi B, Stucchi C, Valdagni R. Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients: Results from a large pooled population. Phys Med. 2016 Dec; 32(12):1690-7
DOI: 10.1016/j.ejmp.2016.09.018

03.04 RADAR

Moulton CR, House MJ, Lye V, Tang CI, Krawiec M, Joseph DJ, Denham JW, Ebert MA. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol. 2016 Oct; 11(1):144
DOI: 10.1186/s13014-016-0719-2

03.04 

RADAR 

Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthew J, Atkinson C, Tai KH, Duchesne G, Christie D, Attia J, 9, Holliday EG, Denham JW. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.  Radiother Oncol. 2016 Oct; 121(1):98-102. 
DOI: 10.1016/j.radonc.2016.07.021

 03.04   RADAR 

Yahya N, Ebert MA, Bulsara M, Kennedy A, Joseph DJ, Denham JW. Independent external validation of predictive models for urinary dysfunction following external beam radiotherapy of the prostate: Issues in model development and reporting. Radiother Oncol. 2016 Aug; 120(2):339-45
DOI: 10.1016/j.radonc.2016.05.010

03.04

RADAR

Yahya N, Ebert MA, Bulsara M, House MJ, Kennedy A, Joseph DJ, Denham JW. Statistical-learning strategies generate only modestly performing predictive models for urinary symptoms following external beam radiotherapy of the prostate: A comparison of conventional and machine-learning methods. Med Phys. 2016 May; 43(5):2040
DOI: 10.1118/1.4944738

03.04 RADAR

Yahya N, Ebert M, Bulsara M, House M, Kennedy A, Joseph D, Denham J. Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models. Radiother Oncol. 2015 Nov; 117(2):277-82
DOI: 10.1016/j.radonc.2015.10.003

03.04

RADAR

Delahunt B, Egevad L, Srigley JR, Steigler A, Murray JD, Atkinson C, Matthews J, Duchesne G, Spry NA, Christie D, Joseph D, Attia J, Denham JW.  Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 ‘RADAR’ trial clinical data. Pathology. 2015 Oct; 47(6):520–25.
DOI: 10.1097/PAT.0000000000000318

03.04 RADAR Yahya N, Ebert MA, Bulsara M, Haworth A, Kennedy A, Joseph DJ, Denham JW. Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial. Radiother Oncol. 2015 July; 116(1):112-8
DOI: 10.1016/j.radonc.2015.06.011

03.04

RADAR

Denham J, Steigler A , Joseph D, Lamb D, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai K-H, Gogna N, Gill S, Tan H, Kearvell R, Murray J, Ebert M, Haworth A, Kennedy A, Delahunt B, Oldmeadow C, Holliday E, Attia J. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer?  Data from the TROG 03.04 RADAR trial.  Rad Oncol. 2015 Jun; 115(3):301-07.
DOI: 10.1016/j.radonc.2015.05.016 

03.04

RADAR

Ebert M, Foo K, Haworth A, Gulliford S, Kennedy A, Joseph D, Denham J. Gastrointestinal dose-histogram effects in the context of dose-volume-constrained prostate radiation therapy: analysis of data from the RADAR prostate radiation therapy trial.  Int J Radiat Oncol Biol Phys. 2015 Mar; 91(3):595-603.

03.04

RADAR

Ebert M, Bulsara M, Haworth A, Kearvell R, Richardson S, Kennedy A, Spry N, Bydder S, Joseph D, Denham J. Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: Are the results reflected in observed toxicity rates? J Med Imag Radiat Oncol. 2015 Feb; 59(1):99-108

03.04

RADAR

Elsner K, Francis K, Hruby G, & Roderick S. Quality improvement process to assess tattoo alignment, set-up accuracy and isocentre reproducibility in pelvic radiotherapy patients. J Med Radiat Sci. 2014 Dec; 61(4):246-52.

03.04

RADAR

Denham J, Nowitz M, Joseph D, Duschesne G, Spry N, Lamb D, Matthews J, Turner S, Atkinson C, Tai K-H, Gogna K, Kenny L, Diamond T, Smart R, Rowan D, Moscato P, Vimieiro R, Woodfield R, Lynch K, D’Este C, McElduff P, Steigler A, Kautto A, Ball J. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the TROG 03.04 RADAR trial for locally advanced prostate cancer. BJUI. 2014 Sep; 114(3):344-53. 


Brain & Central Nervous System

 08.05 WBRT

Hong A; Hallock H; Valenzuela M; Lo S;  Paton E; Ng D; Dhillon H; Jacobsen K; Reisse C; Fogarty G. Hippocampal avoidance whole brain radiation therapy is associated with preservation of hippocampal volume at six months: a case series. Neurooncol Open Access 2017 Mar; 1:1.
DOI: 10.21767/2572-0376.100017

 08.05 

 WBRT  

Fogarty G, Hong A, Dolven-Jacobsen K, Reisse C, Burmeister B, Haydu L, Dhillon H, Steel V, Shivalingam B, Drummond K, Vardy J, Nowak A, Hruby G, Scolyer R, Mandel C, Thompson J. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes 2015 May; 8(192).
DOI: 10.1186/s13104-015-1153-5

08.02 GBM

Perry J, Laperriere N, O'Callaghan C, Brandes A, Menten J, Phillips C, Fay m, Nishikava R, Carncross J, Roa W, Osoba D, Rossiter J, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Goldinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert B, Wick W, Ding K, Mason W. Short-course radiation plus temozolomide in elderly patients with glioblastoma. New Engl J Med. 2017 Mar; 376(11):1027-37.
DOI: 10.1056/NEJMoa1611977

06.01 - Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ.  Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC 22033-26033 clinical trial. Eur J Cancer. 2018 May; 94:168-78.
06.01 -

Baumert B, Hegi M, Van Den Bent J, Von Deimling A, Gorlia T, Hoang-Xuan K, Brandes A, Kantor G, Taphoorn M, Ben Hassel M, Hartmann C, Ryan G, Capper D, Kros J, Kurscheild S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg J, Feuvret L, Reijneveld J, Chinot O, Gijtenbeek J, Rossiter J, Dif N, Balana C, Barvo-Marques J, Clement P, Marosi C, Tzuk-Shina T, Nordal R, Rees J, Lacombe D, Mason W, Stupp R.  Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1521-32.
DOI: 10.1016/S1470-2045(16)30313-8

06.01

-

Reijneveld J, Taphoorn M, Coens C, Bromber J, Mason W, Hoang-Xuan K, Ryan G, Beh Assel M, Enting R, Brandes A, Wick A, CHinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulous V, Gorlia T, Bottomley A, Stupp R, Baumert B. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1533-42.
DOI: 10.1016/S1470-2045(16)30305-9

98.05 -

Roos D, Wirth A, Burmeister B, Spry N, Drummond K, Beresford J and McClure B. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol. 2006 Sep; 80(3):318-22.
DOI: 10.1016/j.radonc.2006.08.004

Back to top


Breast

11.01  SUPREMO  

Thomas J, Hanby A, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron D, Bartlett J, Bowman A, Piper T, Cunningham C, Canney P, Kunkler I. The BIG 2.04 MRC/EORTC  SUPREMO Trial - Pathology quality assurance of a large phase 3 randomised international clinical trial of post mastectomy radiotherapy in intermediate-risk breast cancer. Breast Cancer Res Treat. 2017 Feb; 163(1):63-9.
DOI: 10.1007/s10549-017-4145-4

 10.02 

 RAPID  

Peterson DJ, Truong PT, Parpia S, Olivotto IA, Berrang T, Kim D-H, Kong I, Germain I, Nichol A, Akra M, Roy I, Reed M, Fyles A, Trotter T, Perera F, Balkwill S, Lavertu S, Elliott E, Julian JA, Levine MN, Whelan TJ.  Predictors of adverse cosmetic outcome in the RAPID trial: An exploratory analysis. Int J Radiat Oncol Biol Phys. 2015 Apr; 91(5):968-76.

10.02

RAPID

Olivotto  IA, Whelan  TJ, Parpia S, Kim DH, Berrang T, Truong  PT, Kong I, Cochrane B, Nichol A, Roy I, Germain I, Akra M, Reed M, Fyles A, Trotter T, Perera F, Beckham W, Levine MN, Julian JA. Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy. J Clin Oncol. 2013 Nov; 31(32):4038-45. 

06.02

APBI

Kron T, Willis D, Link E, Lehman M, Campbell G, O’Brien P and Chua B. Can we predict plan quality for external beam partial breast irradiation: Results of a multicenter feasibility study (Trans Tasman Radiation Oncology Group Study 06.02). Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):817-824.

06.02

APBI

Kron T, Willis D, Bignell F, Martland J, Donnell S, May S, Chua BH. Centre credentialing for Trans Tasman Radiation Oncology Group trial 06.02: multicentre feasibility study of accelerated partial breast irradiation. J Med Imag Radiat Oncol. 2009 Aug; 53(4):412–18.

06.02

APBI

Kron T, Willis D, Miller J, Hubbard P, Oliver M, Chua B. A spreadsheet to determine the volume ratio for target and breast in partial breast irradiation. Australas Phys Eng Sci Med. 2009 Jun; 32(2):98-104.
 

03.05

MA20

Whelan T.J, Olivotto I, Parulekar W, Ackerman I, Chua B, Nabid A, Vallis K, White J, Rousseau P, Fortin A, Pierce L, Manchul L, Chafe S, Nolan M, Craighead P, Bowen J, McCready D, Pritchard K, Gelmon K, Murray Y, Chapman J, Chen B, Levine, M. Regional nodal irradiation in early-stage breast cancer. N Eng J Med. 2015 Jul; 373(4):307-16. 

89.02

-

Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, et al. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. Australas Radiol. 1999 May; 43(2):220-26. 

89.02

-

Christie DRH, O'Brien MY, Christie JA, Kron T, Ferguson SA, Hamilton CS et al. A comparison of methods of cosmetic assessment in breast conservation treatment. Breast. 1996 Oct; 5(5):358-67

89.02

-

Denham JW, Hamilton CS, Christie D, O'Brien M, Bonaventura A, Stewart JF et al. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer - toxicity and dose modification: a Trans-Tasman Radiation Oncology Group multi-institution study. Int J Radiat Oncol Biol Phys. 1995 Jan; 31(2): 305-13. 
 

Back to top


Gastrointestinal

08.08  TOPGEAR 

Leong T, Smithers M, Haustermans K, Michael M, Gebski V, Miller D, Simes J, Zalcberg J, Boussioutas A, Findlay M, O'Connell R, Verghis J, Willis D, Kron T, Crain M, Murray W, Lordick F, Swallow C, Darling G, Wong R. TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG (formerly NCIC CTG). Ann Surg Oncol. 2017 Aug; 24(8): 2252-58
DOI: 10.1245/s10434-017-5830-6

03.02

 - 

Leong T, Lim Joon D, Willis D, Jayamoham J, Spry N, Harvey J, Di lulio J, Milner A, Mann GB, Michael M. Adjuvant chemoradiation for gastric cancer using epirubicin, Cisplatin, and 5-fluorouracil before and after three-dimensional Conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the trans-tasman radiation Oncology group. Int J Radiat Oncol Biol Phys. 2011 Mar; 79(3):690-95.

03.01 - Penniment M, De Ieso P, Harvey J, Stephens S, Au H, O'Callaghan C, Kneebone A, Ngan S, Ward I, Roy R, Smith J, Nijjar T, Biagi J, Mulroy L, Wong R; TROG 03.01/CCTG ES.2 group. Lancet Gastroenterol Hepatol. 2018 Feb; 3(2):p114-24.
DOI: 10.1016/S2468-1253(17)30363-1
01.04  -

McLachlan S, Fisher R, Zalcberg J, Solomon M, Burmeister B, Goldstein D, Leong T, Ackland S, McKendrick J, McClure B, Mackay J, Ngan S. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). Eur J Cancer. 2016 Mar; 55:15-26

01.04

-

Ngan S, Burmeister B, Fisher R, Solomon M, Goldstein D, Joseph D, Ackland S, Schache D, McClure B, McLachlan S, McKendrick J, Leong T, Hartopeanu C, Zalcberg and Mackay J. Randomized trial of short course radiotherapy versus long course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer (TROG01.04). J Clin Oncol. 2012 Nov; 30(31):3827-33.

99.02

-

 Matthews J, Burmeister B, Borg M, Capp A, Joseph D, Thompson KM, Thompson PI, Harvey JA, Spry NA. T1-2 anal carcinoma requires elective inguinal radiation treatment- the results of Trans Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol. 2011 Jan; 98(1):93-98.

98.01

-

Ngan SYK, Fisher R, Burmeister BH, Mackay J, Goldstein D, Kneebone A, Schache D, Joseph D, McKendrick J, Leong T, McClure B, Rischin D. Promising results of a co-operative group phase II trials of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801). Dis Colon Rectum. 2005 Jul; 48(7):1389-96.

 98.01 

-

Ngan SYK, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A, MacKay JR, Joseph D, Bell A and Goldstein D. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of rectum. A phase II trial for the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2001 Jul; 50(4):883-87. 

96.02

-

Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lamb DS, Joseph D Delaney G, Christie D, Jamieson G, Smithers BM, Ackland S, Walpole E. Relapse patterns after chemo-radiation for carcinoma of the oesophagus. J Clin Oncol. 2003 May; 15(3): 98–108.

96.02

-

Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P and Spry N. Causes for increased myelosuppression with increasing age in patients with esophageal cancer treated by chemo-radiation. Eur J Cancer. 1999 Jun; 35(6):921-27. 
 

94.01

-

Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005 Sep; 6(9):659-68.

89.04

-

Burmeister BH, Smithers BM, Denham JW. Combined modality therapy for carcinoma of the oesophagus: current status and future directions. Med J Aust. 1997 Oct; 167(7):349-50.

89.04

-

Smithers BM, Devitt P, Jamieson GG, Bessell J, Gotley D, Gill PG et al. A combined modality approach to the management of oesophageal cancer. Eur J Surg. 1997 Jun; 23(3):219-23.

89.04

-

Denham J and on behalf of the Trans-Tasman Radiation Oncology Group (TROG). Response to L. R. Coia re factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother Oncol. 1997 Jan; 42(1): 91-2. (Letter)

89.04

-

MacKean J, Burmeister BH, Lamb DS, Denham JW. Concurrent chemo-radiation for oesophageal cancer - Factors influencing myelotoxicity. Australas Radiol. 1996 Nov; 40(4):424-29.

89.04

-

Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS et al. Factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother Oncol. 1996 Jul; 40(1):31-4

89.04

-

Burmeister BH, Denham JW, O'Brien M, Jamieson GG, Gill PG, Devitt P et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicentre study. Int J Radiat Oncol Biol Phys. 1995 Jul; 32(4):997-1006. 

89.04

-

Denham JW. Oesophageal cancer - guarded optimism. Med J Aust. 1994 Jun; 160(11):669-70. 

89.03

-

Lamb DS, Denham JW, Morum PE, Gray AJ. Long-term results of accelerated radiation treatment for advanced head and neck cancer. A Trans-Tasman Radiation Oncology Group (TROG) Phase II study. Radiother Oncol. 1998 Oct; 49(1):29-32. 

Back to top


Gynaecological

08.04  PORTEC-3 de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb; 19(3):295–309.
 08.04   PORTEC-3

Jameson M, Mcnamara J, Bailey M, Metcalfe P, Holloway L, Foo K, Do V, Mileshkin L, Creutzberg, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. J Med Imag Radia Oncol.  2016 Sep; 60(4):554-59
DOI: 10.1111/1754-9485.12447

 08.04 

 PORTEC- 

de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger P, Ledermann J, Khaw P, Colombo A, Fyles A, Baron M, Kitchener H, Nijman H, Kruitwagen R, Nout R, Verhoeven-Adema K, Smit V, Putter H, Creutzberg C. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial, for the PORTEC study group. Lancet Oncol. 2016 Jul; 17(8):1114-26 
DOI: 10.1016/S1470-2045(16)30120-6

Back to top


Head & Neck

 12.03 

 EAT 

Beck A, Baker A, Britton B, Wratten C, Bauer J, Wolfenden L, Carter G. Fidelity considerations in translational research: Eating As Treatment - a stepped wedge, randomised controlled trial of a dietitian delivered behaviour change counselling intervention for head and neck cancer patients undergoing radiotherapy. TRIALS. 2015 Oct; 16:465. 

12.03

EAT 

Britton B, McCarter K, Baker A, Wolfenden L, Wratten C, Bauer J, Beck A, McElduff P, Halpin S, Carter G. Eating As Treatment (EAT) study protocol: a stepped-wedge, randomised controlled trial of a health behaviour change intervention provided by dietitians to improve nutrition in patients with head and neck cancer undergoing radiotherapy. BMJ Open. 2015 Jul; 5(7):e008921.

07.04 CETUXIMAB 

Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D. Prospective study of cetuximab, carboplatin and radiotherapy for patients with locally advanced head and neck squamous cell cancer (HNSCC) unfit for cisplatin. Int J Radiat Oncol Biol Phys. 2017 Jul; 98(4);948-54.
DOI: 10.1016/j.ijrobp.2017.02.088

07.03 RadioHUM

Macann A, Fauzi F, Simpson J, Sasso G, Krawitz H, Fraser-Browne C, Manitz J, Raith A. Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy. Oral Oncology. 2017 Dec; 75:75-80.
DOI: 10.1016/j.oraloncology.2017.10.021

07.03

 RadioHUM 

Macann A, Fua  T, Milross C, Porceddu S, Penniment  M, Wratten C, Krawitz H, Poulsen M, Tang CI, Morton RP, Hay KD, Thomson V, Bell ML, King MT, Fraser-Browne CL, Hockey HP. Phase III trial of domiciliary humidification to mitigate acute mucosal toxicity during radiotherapy for head and neck cancer: First report of Trans Tasman Radiation Oncology Group (TROG) 07.03 RadioHUM study. Int J Radiat Oncol Biol Phys. 2014 Mar; 88(3):572-79

05.01 POST

Porceddu S. Post-operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: A randomized Phase III trial (Trans Tasman Radiation Oncology Group 05.01 Trial) - Post Operative Skin Trial (POST), J Clin Oncol. Article in press. DOI: 10.1200/JCO.2017.77.0941

02.02  HeadSTART 

Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Van Den Bogaert W, Wratten C, Rischin D. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys. 2017 Mar; 97(4): 678-86. 
DOI: 10.1016/j.ijrobp.2016.03.017

02.02

 HeadSTART 

Ohri N, Shen X, Dicker A, Doyle L, Harrison A, Showalter T. Radiotherapy Protocol Deviations and Clinical Oucomes: A Meta-Analysis of Cooperative Group Clinical Trials. J Natl Cancer Inst. 2013 Mar; 105(6):387-93.

02.02

 HeadSTART 

Lim AM, Young RJ, Collins M, Fox SB, McArthur GA, Corry J, Peters L, Rischin D, Solomon B. Correlation of Ataxia-Telangiectasia-Mutated gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncol. 2012 Aug; 48(8):689-702.  

02.02

 HeadSTART 

Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, Graves E, Hicks RJ, McArthur GA, Peters L, O’Sullivan B, Giacia A, Rischin D. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without Tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res. 2012 Jun; 18(6):1798-807.

02.02

 HeadSTART 

Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D, McArthur GA, Young RJ, Giaccia A, Peters L, Le QT. Prognostic significance of Plasma Osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 Phase III Trial. Clin Cancer Res. 2012 Jan; 18(1):301-07. 

02.02

 HeadSTART 

Young R, Rischin D; Fisher R; et al. Relationship between Epidermal Growth Factor Receptor Status, p16(INK4A), and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiol Biomar Prev. 2011 Jun; 20(6):1230-37. 

02.02

 HeadSTART 

Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O’Sullivan B, Kenny LM, McArthur GA. Prognostic Significance of p16INK4A and Human Papillomavirus in patients with Oropharyngeal Cancer Treated on TROG 02.02 Phase III trial. J Clin Oncol. 2010 Sep; 28(27):4142-48.

02.02

 HeadSTART 

Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D. Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. J Clin Oncol. 2010 Jun; 28(18):2996-3001.

02.02

 HeadSTART 

Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010 Jun; 28(18):2989-95.

98.02

-

Corry J, Peters L, Fisher R, Macann A, Jackson M, McClure B, Rischin D. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders - Results of Trans Tasman Radiation Oncology Group study 98.02. Head Neck. 2008 Jun; 30(6):737-42.   

98.02

-

Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S and Peters LJ. Prognostic significance of [F-18]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol. 2006 May; 24(13):2098-04.

98.02

-

Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005 Jan; 23(1):79-87. 

91.01

-

Daly T, Poulsen GM, Denham JW, Peters LJ, Lamb DS, Krawitz H, Hamilton C, Keller J, Tripcony L, Walker Q. The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2003 Aug; 68(2): 113–22.

91.01

-

Denham JW and Kron T. Extinction of the weakest. Int J Radiat Oncol Biol Phys. 2001 Nov; 51(3): 807–19.

91.01

-

Poulsen M, Denham J, Peters L, Lamb D, Spry NA, Hindley A, Krawitz, H Hamilton C, Keller J, Tripcony L, Walker Q. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group Study (TROG 91.01). Radiother Oncol. 2001 Aug; 60(2):113-22. 

91.01

-

Poulsen M, Denham JW, Spry N, Lamb D, Peters L, Williamson S and L Tripcony. Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study. Acute toxicity analysis of a phase III randomised trial of accelerated. Australas Radiol. 1999 Nov; 43(4):487-94. 

91.01

-

Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, O'Brien P, Spry NA, Penniment  M, Krawitz H, Williamson  S,  Bear J,  Tripcony  L. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol. 1999 Aug; 52(2):157-64. 

91.01

-

Hamilton CS, Walker Q, Poulsen M, Spry N, Lamb D, Denham JW and Steigler A. Quality Assurance Audit in an Australasian Phase III Trial of Accelerated Radiotherapy for Head and Neck Cancer (TROG 91. 01). Australas Radiol. 1999 May; 43(2):227-32. 

89.03 - Lamb DS, Denham JW, Morum PE, Gray AJ. Long-term results of accelerated radiation treatment for advanced head and neck cancer. A Trans-Tasman Radiation Oncology Group (TROG) Phase II study. Radiother Oncol. 1998 Oct; 49(1):29-32. 
- - Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D. Prospective study of cetuximab, carboplatin and radiotherapy for patients with locally advanced head and neck squamous cell cancer (HNSCC) unfit for cisplatin. Int J Radiat Oncol Biol Phys. 2017 Jul; 98(4);948-54.
DOI: 10.1016/j.ijrobp.2017.02.088
- - Macann A, Fauzi F, Simpson J, Sasso G, Krawitz H, Fraser-Browne C, Manitz J, Raith A. Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy. Oral Oncology. 2017 Dec; 75:75-80.
DOI: 10.1016/j.oraloncology.2017.10.021

Back to top


 

 

Lung

13.01  SAFRONII   Pham D, Hardcastle N, Foroudi F, Kron T,  Bressel  M, Hilder B, Chesson B, Oates R, Montgomery R, Ball D, Siva S. A Multidisciplinary Evaluation of a Web-based eLearning Training Programme for SAFRON II (TROG 13.01): A Multicentre Randomised Study of Stereotactic Radiotherapy for Lung Metastases. Clin Oncol. 2016 Sep; 28(9):e101-08.
DOI: 10.1016/j.clon.2016.03.005
09.02  CHISEL Kron T, Chesson B, Hardcastle N, Crain M, Clements N, Burns M, Ball D. Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel) a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer. Br J Radiol. Article in press
DOI: 10.1259/bjr.20170737

 09.02 

 CHISEL 

Hardcastle N, Clements N, Chesson B, Aarons Y, Cramb J, Siva S, Wanigaratne DM, Ball D, Kron T. Results of patient specific quality assurance for patients undergoing stereotactic ablative radiotherapy for lung lesions. Australas Phys Eng Sci Med. 2014 Mar; 37(1):45-52. 

09.02

CHISEL

Clements N, Kron T, Franich R, Dunn L, Roxby P, Aarons Y, Siva S, Chesson B, Duplan D, Ball D.  The effect of irregular breathing patterns on internal target volumes in four-dimensional CT and cone-beam CT images in the context of stereotactic lung radiotherapy. Med Phys. 2013 Feb; 40(2):021904. 

09.02

CHISEL

Siva S, Shaw M, Chesson B, Gill S and Ball D. Analysis of the impact of chest wall constraints on eligibility for a randomized trial of stereotactic body radiotherapy of peripheral stage I non-small cell lung cancer. J Med Imag Radiat Oncol. 2012 Dec; 56(6):654-60.

09.02

CHISEL

Kron T, Clements N, Aarons Y, Dunn L, Cheeson B, Miller J, Roozen K, Ball D. Radiochromic film for individual patient QA in extracranial stereotacic lung radiotherapy. Radiat Meas. 2011; 46:1920-23.

09.02

CHISEL

Clements N, Kron T, Dunn L, Aarons Y, Cheeson B, Miller J, Ball D. Patient-specific QA for motion management in hypofractionated lung radiotherapy. Med Phys. 2010; 37: 3420.

03.07

-

Burmeister BH, Michael M, Burmeister E, Cox S, Lehman M, Wirth A, Horwood K, Sasso G, Forouzesh B, Ball D. A randomised phase II trial of 2 regimens of moderate dose chemoradiation therapy for patients with non small cell lung cancer not suitable for curative therapy - Trans Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol. 2011 Dec; 6(12):2076-82.

99.05 -

Cox A, Akhurst T, Bressel M, MacManus M, Ball D. Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapy. Radiother and Oncol. 2017 Jul; 124(1):25-30
DOI: 10.1016/j.radonc.2017.06.004

99.05

-

Ball D, Fisher R, McClure B.  Response to Dahele and Senan. Radiother Oncol.12 October 2013;109 (1):180-181.(Refers to Max Dahele, Suresh Senan. What causes early mortality in patients with large tumors receiving radical chemo-radiotherapy for non-small cell lung cancer? In response to Ball et al. Radiother Oncol. 2013 Sep; 109: 178-82.

99.05

-

Ball D, Fisher R, Burmeister B, Poulsen M, Graham P, Penniment M, Vinod S, Krawitz H, Joseph D, Wheeler G, McClure B. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol. 2013 Mar; 106(3):305-11.

99.05

-

Ball DL, Fisher R, Burmeister B, Graham P, Joseph D, Penniment M, Krawitz H, Wheeler G, Poulsen M, Vinod S and McClure B. Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol. 2006 Sep; 1(7):667-72.

Back to top


Lymphoma

99.04

   

Christie D, Dear K, Le T, Barton M, Wirth A, Porter D, Roos D, Pratt G. Limited Chemotherapy and Shrinking Field radiotherapy for Osteolymphoma (primary bone lymphoma): Results from the Trans Tasman radiation Oncology Group 99.04 and Australasian Leukemia and Lymphoma Group LY02 Prospective Trial. Int J Radiat Oncol Biol Phys. 2011 Jul; 80(4):1164-70.

99.04

-

Christie D, Le T, Watling K, Cornes D, O’Brien P, Hitchins R. Quality assurance audit: A prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02). J Med Imag Radiat Oncol. 2009 Apr; 53(2):203–06.

99.04

-

Christie DR, Gabriel GS and Dear K. Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? J Intern Med. 2007 Oct; 37(10):680-86.

99.03 - MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour J. A Randomized Trial of Systemic Therapy after involved-field Radiotherapy in patients with Early Stage Follicular Lymphoma: TROG 99.03. J Clin Oncol. 2018 Oct; 36(29):2918-25. DOI: 10.1200/JCO.2018.77.9892

99.01

-

Wirth A, Grigg A, Wolf M, Goldstein D, Johnson C, Davis S, Dutu G, Kypreos P, Smith C, Kneebone A, Herzberg M, Joseph D, Catalano J, Roos D, Reynolds J. Risk and Response Adapted Therapy for Early Stage Hodgkin Lymphoma: A Prospective Multi-Centre Study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. Leuk Lymphoma. 2011; 52(5):786–95. 

92.01

-

O’Brien PC, Roos DE, Pratt G, Liew K-H, Barton MB, Poulsen MG, Olver IA, Trotter GE. Combined-modality Therapy for Primary Central Nervous System Lymphoma: Long-term Data from a Phase II Multi-center Study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys. 2006 Feb; 64(2):408-13.

92.01

-

O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I and Trotter G. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000 Feb; 18(3):519-26.

92.01

-

O'Brien PC, Roos D, Liew K-H, Trotter G, Barton M, Walker Q et al. Preliminary results of combined Chemotherapy and radiotherapy for non-AIDS primary Central Nervous System lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med J Aust. 1996 Oct; 165(8):424-27. 

Back to top


Skin

09.03

MP3

Poulsen M, Macfarlane D, Veness M, Estall V, Hruby G, Kumar M, Pullar A, Tripcony L, Rischin D. Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03. J Med Imag Radiat Oncol. Article in press
DOI: 10.1111/1754-9485.12705

09.03

MP3

Finnigan R, Hruby G, Wratten C, Keller J, Tripcony L, Dickie G, Rischin D, Poulsen M. The impact of pre-radiation residual disease volume on time to locoregional failure in cutaneous merkel cell carcinoma – A TROG substudy. Int J Radiat Oncol Biol Phys. 2013 May; 86(1):91-5.

 08.09 

 RTN2 

Foote M. TROG 08.09 ANZMTG 01.09. An International Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. J Dtsch Dermatol Ges. 2013; 11:57-58.

02.01

-

Henderson M, Burmeister B, Ainslie J, Fisher R, Di Iulio J, Smithers MB, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry B, Babington S, Duprat J, Hoekstra H, Thompson J. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.  Lancet Oncol. 2015 Sep; 16(9):1049-60.

02.01

-

Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Kerwin S, Scolyer RA, Curruthjers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.  Lancet Oncol. 2012 Jun; 13(6):589-97.

96.07

-

Poulsen M, Rischin D, Porter I, Walpole E, Harvey J, Hamilton C, Keller J, Tripcony L. Does Chemotherapy improve survival in high risk stage I and II Merkel Cell Carcinoma of the skin? Int J Radiat Oncol Biol Phys. 2006 Jan; 64(1):114-19.

96.07

-

Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J, Hamilton C, Keller J, Tripcony L. High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07. J Clin Oncol. 2003 Dec; 21(23): 4371-76.

96.07

-

Poulsen M, Rischin D, Walpole E, Harvey J, Macintosh J, Ainslie J, Hamilton C, Keller J Tripcony L. Analysis of toxicity of Merkel Cell Carcinoma of the skin treated with synchronous carboplatin/etopside and radiation: A Trans-Tasman Radiation Oncology Group study - TROG 96. 07. Int J Radiat Oncol Biol Phys. 2001 Sep; 51(1):156-63. 

96.06

-

Burmeister B. Smithers M,  Burmeister E, Baumann K, Davis S, Krawitz H, Johnson C and Spry N. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma - Trans Tasman Radiation Oncology Group (TROG) study 96.06. Radiother Oncol. 2006 Nov; 81(2):136–42.

96.06

 

Burmeister BH, Smithers BM, Davis S, Spry N, Johnson C Krawitz H, Baumann KC. Radiation therapy following nodal surgery for melanoma: An analysis of toxicity. ANZ J Surg. 2002 May; 72(5):344–48. 

Back to top


Symptom Management

 04.01 

      

Graham PH, Plant N, Browne L,  Borg M,  Capp A,  Delaney G, Harvey J,  Kenny L, Francis M,  Zissiadis Y.  A paired double blind randomised comparison of a moisturising durable barrier cream (MDBC) to 10% glycerine ("Sorbolene") cream in the prophylactic management of post-mastectomy irradiation skin care. Trans Tasman Radiation Oncology Group (TROG) 04.01. Internat J Radiat Oncol Biol Phys. 2013 May; 86(1):45-50.  

04.01

-

Graham P, Plant N, Graham J, Browne L, Martin Borg M, Capp A, Delaney, Harvey J, Kenny L, Francis M, Zissiadis Y.  Digital photography as source documentation of skin toxicity: An analysis from the Trans Tasman Radiation Oncology Group (TROG) 04.01 Post-Mastectomy Radiation Skin Care Trial. JMIRO. 2012 Aug; 56(4):458-63.

03.08

-

Chow E, van der Linden Y, Roos DE, Hartsell WF, Hoskin P, Wu Jackson S, Brundage M, Nabid A, Tissing-Tan C, Oei B, Babington S, Demas W, Wilson F, Meyer R, Chen B, Wong R.  Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.  Lancet Oncol. 2014 Feb; 15(2):164-71.

03.08

-

Roos D. Response to “Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: Results from three Canadian centers”. Int J Rad Onc Biol Phys. 2010 Oct; 78(2):637.

03.08

-

Chow E, Hoskin P, Wu J, Roos D, van der Linden Y, Hartsell W, Vieth R, Wilson C, Pater J. A Phase III International Randomised Trial Comparing Single with Multiple Fractions for Re-irradiation of Painful Bone Metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. J Clin Oncol. 2006 Mar; 18 (2):125-128. (Editorial)

01.05

-

Graham PH, Capp A, Delaney G, Goozee G, Hickey B, Turner S, Browne L, Milross C, Wirth A. A pilot randomised comparison of Dexamethasone 96 mg versus 16mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex Study. J Clin Oncol. 2006 Feb; 18(1):70-6.

98.04

-

Bydder S, Spry NA, Christie DRH, Roos D, Burmeister BH, Krawitz H, Davis S, Joseph DJ, Poulsen M, Berry M. A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australas Radiol. 2003 Sep; 47(3):284–88.

96.05

-

Pollicino CA, Turner SL, Roos DE, O’Brien PC. Costing the components of pain management. Analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): One versus five fractions for neuropathic bone pain. Radiother Oncol. 2005 Sep; 76(3):264–69.

96.05

-

Roos D, Turner S, O'Brien P, Smith J, Spry N, Burmeister B, Hoskin P, Ball D. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol. 2005 Apr; 75(1):54-63.

96.05

-

Roos DE, Davis SR, Turner SL, O’Brien PC, Spry NA, Burmeister BH, Hoskin PJ and Ball DL. Quality assurance experience with the randomised neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05). Radiother Oncol. 2003 May; 67(2):207–12.

96.05

-

Roos DE, O'Brien PC, Smith JG, Spry NA, Hoskin PJ, Burmeister BH, Turner S and Bernshaw D. A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96. 05). Int J Radiat Oncol Biol Phys. 2000 Mar; 46(4): 975-81. 

96.05

-

Roos DE, Davis SR, O'Brien PC, Hoskin PJ, Spry NA, Burmeister BH, Turner S and Bernshaw D. Eligibility audits for the randomised neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group Study, TROG 96. 05). Australas Radiol. 2000 Aug; 44(3):303-07. 

95.02

-

O'Brien PC, Franklin CI, Joseph DJ, Spry NS, Denham JW. Acute symptoms, not rectally administered Sucralfate, predict for late radiation proctitis. Longer-term follow-up of a Phase 3 trial – Trans-Tasman Radiation Oncology Group (TROG). Int J Radiat Oncol Biol Phys. 2002 Oct; 54(2):442–49.

95.02

-

O’Brien PC, Franklin CI, Dear KBG, Hamilton CS, et al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis: Trans-Tasman Radiation Oncology Group (TROG). Radiother Oncol. 1997 Nov; 45(2):117–23.D

Back to top


TROG Projects

 ANROTAT 

Brown E, Cray A, Haworth A, Chander S, Lin R, Subramanian B,  Ng  M. Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. J Med Rad Sci. 2015 Jun; 62(2):99-107.

ANROTAT

Duchesne G, Grand M, Kron T, Haworth A, Corry J, Jackson M, Burmeister B. (2014). Trans Tasman Radiation Oncology Group: Development of the Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Framework. J Med Imag Radiat Oncol. 2015 Jun; 59(3):363-70.

ANROTAT

Carter H, Martin A, Schofield D, Duchesne G, Haworth A, Hornby C, Sidhom M, Jackson M. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. Radiother Oncol. 2014 Aug; 112(2):187-93. 

Back to top


Other

Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018 Jan; 126(1):3-24.
DOI: 10.1016/j.radonc.2017.10.016

Christie D, Sharpley C.  The successful contribution by the Trans-Tasman Radiation Oncology Group to intergroup radiation oncology trials (2010-2012) and a proposal for accrual definitions. Radiother Oncol. 2014 Jul; 112(1):153-54.  

Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, Maingon P, Nutting C, O’Sullivan B, Porceddu S, Lengele B.  Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014 Jan; 110(1):172-81.

Christie D. Accrual to Trans-Tasman Radiation Oncology Group-sponsored trials 2010-2012. J Med Imag Radiat Oncol. 2013 Aug; 57(4):499-502.  

Grand M, O’Brien P. Obstacles to participation in randomised cancer clinical trials: a systematic review of the literature. J Med Imag Radiat Oncol. 2012 Feb; 56(1):31-9. 

Chen Y, Trotti A, Coleman CN, Machtay M, Mirimanoff RO, Hay J,  O’Brien PC, El-Gueddari B, Salvajoli JV, Jeremic B. Adverse Event Reporting And Developments In Radiation Biology After Normal Tissue Injury: International Atomic Energy Agency Consultation. Int J Radiat Oncol Biol Phys. 2006 Apr; 64(5):1442–51.

Christie D, Sharpley C, Curtis T. Improving the Accuracy of a Photographic Assessment System for Breast Cosmesis. J Clin Oncol. 2005 Feb; 17(1):27-31.
DOI: Unavailable

Denham JW and Atkinson C.  Where is your evidence? Australas Radiol. 1999; 43(1):124–25. 

Atkinson CH, Hamilton CS, Wynne CJ. Radiotherapy planning for lung cancer: Can we do better? Australas Radiol. 1994 Nov; 38(4):303-04. 

Denham JW, Hamilton CS, Joseph DJ, et al. The use of simulator and CT information in the planning of radiotherapy for non-small cell lung carcinoma; an Australasian pattern of practice study. Lung Cancer. 1993 Feb; 8(5-6):275-84. 
DOI: 10.1016/0169-5002(93)90476-E

Hamilton CS and Denham JW. Dose normalisation and specification: from woe to go. Australas Radiol. 1992 May; 36(2):137-41. 
DOI: 10.1111/j.1440-1673.1992.tb03101.x

Hamilton CS, Denham JW, Joseph DJ, et al. Treatment and planning decisions in non-small cell carcinoma of the lung: an Australasian pattern of practice study. J Clin Oncol. 1992 May; 4(3):141-47. 
DOI: Unavailable

Gill PG, Denham JW, Jamieson GG, Devitt PH, Yeoh E, Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol. 1992 Jul; 10(7):1037-43.
DOI: Unavailable

Lamb DS, Spry NA, Gray AJ, Johnson AD, Alexander SR, Dally MJ. Accelerated fractionation radiotherapy for advanced head and neck cancer. Radiother Oncol. 1990 Jun; 18(2):107-16.
DOI: 10.1016/0167-8140(90)90136-K

Back to top


Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018 Jan; 126(1):3-24.
DOI: 10.1016/j.radonc.2017.10.016

Our Research

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.